PHVS
VENTE TOTALE: 4 584 titres (~159 840,18 $ US)
- Insiders
- Modig Berndt
- Total bought
- —
- Total sold
- $159,840
- Last activity
- 2026-08-14
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-26
PHVS is a pre-revenue biotech with zero operational income, making its strong liquidity position a temporary buffer rather than a sign of fundamental health — reflected in a near-floor fundamentals trend score of 15.
The first sentence of the analysis written for PHVS on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 10.106 | 12.597 | 27.245 | 9.155 | 30.283 | |
| Quick Ratio | 10.106 | 12.597 | 27.245 | 8.933 | 30.283 | |
| Solvency Ratio | -5.808 | -5.680 | -6.870 | -4.124 | -5.976 | |
| Cash Ratio | 9.853 | 12.219 | 26.792 | 8.880 | 29.966 | |
| Price To Earnings Ratio | -7.952 | -7.465 | -9.649 | -4.628 | -8.975 | |
| Price To Earnings Growth Ratio | -0.402 | 1.309 | -0.608 | -0.076 | -0.136 | |
| Forward Price To Earnings Growth Ratio | -0.402 | 1.309 | -0.608 | -0.076 | -0.136 | |
| Price To Earnings Diluted Ratio | -7.952 | -7.465 | -9.649 | -4.628 | -8.975 | |
| Price To Earnings Diluted Growth Ratio | -0.402 | 1.309 | -0.608 | -0.076 | -0.136 | |
| Price To Book Ratio | 5.151 | 3.735 | 2.537 | 2.364 | 1.878 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -10.181 | -8.288 | -10.460 | -5.244 | -8.604 | |
| Price To Operating Cash Flow Ratio | -10.193 | -8.325 | -10.470 | -5.254 | -8.629 | |
| Debt To Assets Ratio | 0.003 | 0.003 | 0.001 | 0.003 | 0.001 | |
| Debt To Equity Ratio | 0.003 | 0.003 | 0.001 | 0.003 | 0.001 | |
| Debt To Capital Ratio | 0.003 | 0.003 | 0.001 | 0.003 | 0.001 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.111 | 1.088 | 1.038 | 1.124 | 1.035 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.630 | -5.229 | -6.372 | -3.685 | -6.384 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.004 | 1.001 | 1.002 | 1.003 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -5,416.998 | -152.330 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -5,384.328 | -194.617 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -176.460 | -139.448 | -389.482 | -153.753 | -178.268 | |
| Capital Expenditure Coverage Ratio | -832.672 | -223.255 | -1,034.063 | -540.344 | -342.990 | |
| Dividend Paid And Capex Coverage Ratio | -832.672 | -223.255 | -1,034.063 | -540.344 | -342.990 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -6.384 | -4.947 | -5.858 | -2.212 | -4.154 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 10.106 | ▼-2.491 | ▼-7.772 |
| Quick Ratio | 10.106 | ▼-2.491 | ▼-7.727 |
| Solvency Ratio | -5.808 | ▼-0.128 | ▼-0.116 |
| Cash Ratio | 9.853 | ▼-2.366 | ▼-7.689 |
| Price To Earnings Ratio | -7.952 | ▼-0.487 | ▼-0.218 |
| Price To Earnings Growth Ratio | -0.403 | ▼-1.711 | ▼-0.420 |
| Forward Price To Earnings Growth Ratio | -0.403 | ▼-1.711 | ▼-0.420 |
| Price To Earnings Diluted Ratio | -7.952 | ▼-0.487 | ▼-0.218 |
| Price To Earnings Diluted Growth Ratio | -0.403 | ▼-1.711 | ▼-0.420 |
| Price To Book Ratio | 5.151 | ▲1.416 | ▲2.018 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -10.181 | ▼-1.893 | ▼-1.626 |
| Price To Operating Cash Flow Ratio | -10.193 | ▼-1.869 | ▼-1.619 |
| Debt To Assets Ratio | 0.003 | ▼-0.000 | ▲0.001 |
| Debt To Equity Ratio | 0.003 | ▼-0.000 | ▲0.001 |
| Debt To Capital Ratio | 0.003 | ▼-0.000 | ▲0.001 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.111 | ▲0.023 | ▲0.032 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.630 | ▲0.599 | ▲0.630 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▼-0.003 | ▼-0.001 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲1113.866 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲1115.789 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -176.460 | ▼-37.012 | ▲31.022 |
| Capital Expenditure Coverage Ratio | -832.672 | ▼-609.417 | ▼-238.007 |
| Dividend Paid And Capex Coverage Ratio | -832.672 | ▼-609.417 | ▼-238.007 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -6.384 | ▼-1.438 | ▼-1.673 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.40B | $1.00B | $974.2M | $352.9M | $384.8M | |
| Enterprise value | $1.11B | $720.2M | $583.2M | $191.5M | $175.7M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -8.07x | -6.00x | -6.27x | -2.85x | -3.94x | |
| EV / Free cash flow | -8.06x | -5.97x | -6.26x | -2.85x | -3.93x | |
| EV / EBITDA | -6.38x | -4.95x | -5.86x | -2.21x | -4.15x | |
| Net debt / EBITDA | 1.68x | 1.92x | 3.93x | 1.86x | 4.94x | |
| Current ratio | 10.11x | 12.60x | 27.25x | 9.15x | 30.28x | |
| Income quality | 0.79x | 0.91x | 0.93x | 0.89x | 1.04x | |
| Graham net-net | $4 | $5 | $10 | $4 | $7 | |
| Tax burden | 101.1% | 101.4% | 101.1% | 100.9% | 100.2% | |
| Interest burden | 100.0% | 90.9% | 100.0% | 87.2% | 100.7% | |
| Working capital | $269.6M | $266.4M | $383.2M | $148.6M | $204.6M | |
| Invested capital | $271.0M | $267.9M | $383.7M | $149.2M | $204.9M | |
| Return on assets | -58.3% | -46.1% | -25.3% | -45.5% | -20.1% | |
| Operating ROA | -57.3% | -42.2% | -34.2% | -45.7% | -34.6% | |
| Return on tangible assets | -58.3% | -46.1% | -25.3% | -45.5% | -20.1% | |
| Return on equity | -64.8% | -50.1% | -26.3% | -51.1% | -20.8% | |
| Return on invested capital | -62.4% | -54.2% | -25.2% | -57.9% | -26.4% | |
| Return on capital employed | -62.5% | -54.3% | -25.2% | -58.0% | -26.4% | |
| Earnings yield | -12.6% | -13.4% | -10.4% | -21.6% | -11.1% | |
| Free cash flow yield | -9.8% | -12.1% | -9.6% | -19.1% | -11.6% | |
| Capex / Op. cash flow | -0.1% | -0.4% | -0.1% | -0.2% | -0.3% | |
| Capex / Depreciation | 39.3% | 199.6% | 34.9% | 81.3% | 168.1% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+39.7%EV / Sales n/aEV / EBITDA ▼-29.1%EV / Op. cash flow ▼-2.076Earnings yield ▲+0.008
Profitability
Return on equity ▼-0.146Return on assets ▼-0.122Return on invested capital ▼-0.082Return on capital employed ▼-0.082Operating ROA ▼-0.151Income quality ▼-0.118Tax burden ▼-0.002
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-2.492Net debt / EBITDA ▼-0.244Working capital ▲+3119551.000Invested capital ▲+3038130.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+263.1%EV / Sales n/aEV / EBITDA ▼-53.7%EV / Op. cash flow ▼-4.130Earnings yield ▼-0.015
Profitability
Return on equity ▼-0.439Return on assets ▼-0.381Return on invested capital ▼-0.360Return on capital employed ▼-0.361Operating ROA ▼-0.227Income quality ▼-0.256Tax burden ▲+0.010
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-20.178Net debt / EBITDA ▼-3.264Working capital ▲+64983727.000Invested capital ▲+66031799.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-12 Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the second quarter ending on June 30, 2026, and provided a business update.
- 2026-08-06 Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results from the first in-depth qualitative study assessing the experiences of people with AAE-C1INH and validating relevant patient-reported outcome (PRO) measures have been published in Frontiers in Immunology. The study findings directly informed the design of and endpoint selection for the ongoing Phase 3 CREAATE study (NCT07266805) investigating deucrictibant for the prophylaxis and on-demand treatment of AAE-C1INH attacks.
- 2026-08-04 Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment Pharvaris is positioned to build a vertically integrated HAE franchise with deucrictibant in both immediate-release (IR) and extended-release (XR) forms. PHVS''s NDA for deucrictibant IR was accepted by the FDA, with a PDUFA date set for April 23, 2027, following strong Phase 3 RAPIDe-3 results. The CHAPTER-3 Phase 3 data for deucrictibant XR, expected Q3 2026, is the pivotal catalyst determining PHVS''s potential as an end-to-end HAE platform.
- 2026-07-31 Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 2026-07-24 After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over? This late-stage biotech innovator in rare disease therapies reported significant insider selling amid strong one-year share price gains.
- 2026-07-22 Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the publication of a comprehensive review article in Clinical Reviews in Allergy & Immunology providing a state-of-the-art overview of the biology of bradykinin and the bradykinin B2 receptor (B2R), and summarizing the growing body of evidence supporting B2R antagonism as a therapeutic strategy for bradykinin-mediated diseases. Drawing on decades of scientific and clinical research, the article traces the evolution of bradykinin B2 receptor antagonism from foundational discoveries in kinin biology to a clinically validated therapeutic approach.
- 2026-07-15 Here''s Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy Does Pharvaris N.V. (PHVS) have what it takes to be a top stock pick for momentum investors?
- 2026-07-14 Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here''s is How to Trade The mean of analysts'' price targets for Pharvaris (PHVS) points to a 36.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 2026-07-06 Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks ZUG, Switzerland, July 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment (ODT) of Hereditary Angioedema (HAE) attacks. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of April 23, 2027.
- 2026-06-15 Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026 ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the presentations from the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, which took place from June 12-15, 2026, in Istanbul, Turkey.